Semaglutide vs Tirzepatide
The two most effective approved weight loss medications compared—semaglutide (GLP-1 agonist) vs tirzepatide (dual GLP-1/GIP agonist).
Last updated: 2026-02-04
Semaglutide and tirzepatide represent the two most effective approved pharmaceutical treatments for obesity and type 2 diabetes. While semaglutide revolutionised the field as a highly effective GLP-1 receptor agonist, tirzepatide raised the bar further with its dual GLP-1/GIP mechanism.
This comparison examines the key differences between these medications to help healthcare providers and patients make informed treatment decisions.
**Important Note:** Both are prescription-only medications requiring medical supervision. This is educational information, not a recommendation for one over the other.
Quick Comparison Table
| Category | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Weight Loss (Trials) | ~15-17% body weight | ~20-22% body weight |
| HbA1c Reduction | 1.5-2.0% | 2.0-2.5% |
| Dosing | Once weekly | Once weekly |
| Max Dose | 2.4mg (Wegovy) | 15mg (Zepbound) |
| CV Outcomes Data | Yes (SUSTAIN-6, SELECT) | Trials ongoing |
| FDA Approval | 2017 (diabetes), 2021 (obesity) | 2022 (diabetes), 2023 (obesity) |
| Oral Option | Yes (Rybelsus) | In development |
| Manufacturer | Novo Nordisk | Eli Lilly |
| UK Availability | Available (supply constraints) | Available (newer) |
Single vs Dual Receptor Agonism
Semaglutide
Semaglutide: GLP-1 Receptor Agonist
Semaglutide activates only the GLP-1 receptor, producing: - Glucose-dependent insulin secretion - Glucagon suppression - Delayed gastric emptying - Central appetite suppression
This single-receptor approach has proven highly effective, with semaglutide becoming the most-prescribed medication in its class.
Tirzepatide
Tirzepatide: Dual GLP-1/GIP Agonist
Tirzepatide activates both GLP-1 and GIP receptors, producing: - All the effects of GLP-1 activation - Additional GIP-mediated insulin secretion - Enhanced central appetite effects - Possible direct adipose tissue effects
The dual mechanism appears to produce synergistic effects, explaining the superior efficacy seen in trials.
Clinical Trial Evidence
Semaglutide Clinical Studies
Participants: 1,961 adults with obesity without diabetes
Duration: 68 weeks
Semaglutide 2.4mg weekly achieved 14.9% mean weight loss vs 2.4% with placebo. 86% of participants lost ≥5% body weight; 69% lost ≥10%.
Landmark trial establishing semaglutide as most effective obesity medication at time of approval
Participants: 338 adults with obesity without diabetes
Duration: 68 weeks
Semaglutide 2.4mg achieved 15.8% weight loss vs 6.4% with liraglutide 3.0mg. Superiority demonstrated over predecessor GLP-1 agonist.
Direct comparison proving semaglutide's superiority to previous GLP-1 agonist standard
Participants: 17,604 adults with overweight/obesity and cardiovascular disease
Duration: 34 months mean follow-up
Semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% vs placebo. First weight loss medication to show cardiovascular benefit.
Practice-changing trial establishing cardiovascular benefit; unique among GLP-1 agonists for obesity
Participants: 3,297 adults with type 2 diabetes at high CV risk
Duration: 2.1 years
Semaglutide reduced MACE by 26% vs placebo. Significant reductions in non-fatal stroke and non-fatal MI.
Original cardiovascular outcomes trial for semaglutide in diabetes population
Participants: 667 adults with obesity without diabetes
Duration: 68 weeks
Oral semaglutide 50mg daily achieved 15.1% weight loss vs 2.4% placebo. Efficacy comparable to injectable formulation.
Established oral GLP-1 agonist as viable alternative for obesity treatment
Tirzepatide Clinical Studies
Participants: 2,539 adults with obesity without diabetes
Duration: 72 weeks
Tirzepatide 15mg achieved 20.9% mean weight loss vs 3.1% placebo. 95% lost ≥5%; 83% lost ≥10%; 57% lost ≥20% body weight.
Demonstrated unprecedented weight loss efficacy; first medication approaching bariatric surgery results
Participants: 938 adults with obesity and type 2 diabetes
Duration: 72 weeks
Tirzepatide 15mg achieved 14.7% weight loss and 2.1% HbA1c reduction. Superior glycemic and weight outcomes vs placebo.
Confirmed dual efficacy for obesity and diabetes in single medication
Participants: 1,879 adults with type 2 diabetes
Duration: 40 weeks
Tirzepatide 15mg achieved 13.1% weight loss vs 6.7% with semaglutide 1mg. Superior HbA1c reduction (2.3% vs 1.9%).
Only direct head-to-head trial showing tirzepatide superiority to semaglutide
Participants: 469 adults with obesity and moderate-to-severe OSA
Duration: 52 weeks
Tirzepatide reduced apnea-hypopnea index by 63% vs 6% placebo. 43% achieved OSA resolution without CPAP.
Demonstrated metabolic medication can treat obesity comorbidities beyond weight loss
Participants: ~15,000 adults with overweight/obesity and CV disease (projected)
Duration: 4+ years (projected)
Currently enrolling; no results available. Primary endpoint is MACE reduction.
Will determine whether tirzepatide matches semaglutide's cardiovascular benefit profile
Benefits Comparison
Semaglutide Unique Benefits
- Longer track record and more real-world experience
- Extensive cardiovascular outcomes data (SELECT, SUSTAIN-6)
- Oral formulation available (Rybelsus)
- Well-characterised side effect profile
- More widely available currently
Shared Benefits
- Highly effective for weight loss and diabetes
- Once-weekly dosing
- Improvements in blood pressure and lipids
- Reduced cardiovascular risk (proven for semaglutide; expected for tirzepatide)
Tirzepatide Unique Benefits
- Greater weight loss in head-to-head trials
- Superior glucose control
- Potentially better tolerability (some data suggests less nausea)
- Greater liver fat reduction
- Higher rates of diabetes remission
Research & Evidence
Semaglutide Research
STEP trials demonstrated 15-17% weight loss. SUSTAIN-6 and SELECT trials showed cardiovascular risk reduction. Extensive post-marketing data available.
Tirzepatide Research
SURMOUNT trials showed 20-22% weight loss. SURPASS-2 showed superiority over semaglutide 1mg. Cardiovascular outcomes trials ongoing.
Head-to-Head Analysis
SURPASS-2 compared tirzepatide to semaglutide 1mg (not the 2.4mg obesity dose). Tirzepatide showed greater weight loss (12.4kg vs 6.2kg) and HbA1c reduction. A direct comparison at maximum doses has not been conducted.
Protocol Comparison
Semaglutide Protocol
Gradual escalation from 0.25mg to 2.4mg over 16-20 weeks. Take on same day each week.
Tirzepatide Protocol
Gradual escalation from 2.5mg to 15mg over 20+ weeks. Take on same day each week.
Combined Use
These medications should NOT be combined. They have overlapping mechanisms and combination would increase adverse effects without clear additional benefit.
Safety Profiles
Semaglutide Safety
Common: GI effects (nausea, vomiting, diarrhoea). Rare: pancreatitis, gallbladder disease. Contraindicated in MTC/MEN2 history.
Tirzepatide Safety
Similar GI profile to semaglutide; some data suggests slightly better tolerability. Hair loss reported in weight loss trials. Same class warnings apply.
The Verdict: When to Choose Which?
Choose Semaglutide When:
- Cardiovascular risk reduction is priority (proven outcomes data)
- Oral administration preferred (Rybelsus available)
- Longer safety track record important
- Cost or insurance coverage favours semaglutide
Choose Tirzepatide When:
- Maximum weight loss is the primary goal
- Superior glucose control needed
- Significant liver fat/NAFLD present
- Previous inadequate response to GLP-1 agonist
Consider Combining When:
- NOT recommended—overlapping mechanisms, increased risk without benefit
Frequently Asked Questions
Conclusion
Both semaglutide and tirzepatide are highly effective treatments for obesity and diabetes. Tirzepatide shows greater efficacy in trials, while semaglutide has more cardiovascular outcomes data and a longer track record. The choice between them should be individualised based on patient factors, goals, and medical guidance.
*Always consult accredited suppliers and qualified healthcare professionals in your jurisdiction.*
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Semaglutide nor Tirzepatide is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.